Study on the influencing factors of the first-line treatment response to primary immune thrombocytopenia in children

儿童原发性免疫性血小板减少症一线治疗反应影响因素的研究

阅读:1

Abstract

AIMS: This study aims to investigate the factors influencing the first-line treatment response in children with primary immune thrombocytopenia (ITP) and to evaluate the predictive value of these indicators for therapeutic outcomes. METHODS: A total of 140 pediatric patients diagnosed with ITP at the Pediatrics Department of the First Affiliated Hospital of Shihezi University, between June 2022 and December 2024, were enrolled. Patients were grouped according to the type of first-line treatment and treatment response. Laboratory tests such as platelet parameters, P-glycoprotein (P-gp), T lymphocyte subsets, immunoglobulins, and complements were collected and analyzed. RESULTS: Multivariate logistic regression analysis identified elevated P-gp and platelet-to-lymphocyte ratio (PLR), decreased of CD4(+)/CD8(+) ratio and complement 3 (C3) levels as independent risk factors for glucocorticosteroid (GC) treatment failure in children with ITP. Receiver operating characteristic curve (ROC) analysis identified the areas under the curve (AUCs) were 0.772, 0.763, 0.731, and 0.731. The combined model yielded an AUC of 0.919. Elevated PLR and immunoglobulin G (IgG) were independent risk factors for intravenous immune globulin (IVIG) treatment failure.ROC analysis showed that PLR and IgG were predictive of IVIG treatment failure in children with ITP. The AUCs were 0.769 and 0.722, respectively. The combined model yielded an AUC of 0.810. CONCLUSIONS: Elevated P-gp and PLR, along with reduced CD4(+)/CD8(+) ratio and C3 levels, are independent risk factors for GC treatment failure in children with ITP. For IVIG therapy, increased PLR and IgG levels are associated with poor response. These indicators demonstrate predictive value for first-line treatment efficacy, with combined marker analysis offering superior predictive accuracy compared to individual indicators.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。